Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.66 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433971 | 0.84 | DDB1 (0.57) | DDB1CRBNJAK1SCN9APDK4 | |
| SCHEMBL31323392 | 0.84 | DDB1 (0.48) | DDB1CRBNBRD4CDK7CDK13 | |
| SCHEMBL30776681 | 0.82 | DDB1 (0.75) | DDB1CRBN | |
| SCHEMBL30768785 | 0.82 | DDB1 (0.75) | DDB1CRBN | |
| SCHEMBL25586739 | 0.82 | DDB1 (0.75) | DDB1CRBN | |
| SCHEMBL23540247 | 0.82 | DDB1 (0.75) | DDB1CRBNNAMPT | |
| SCHEMBL30026749 | 0.82 | DDB1 (0.75) | DDB1CRBNNAMPT | |
| SCHEMBL31236425 | 0.82 | CRBN (0.75) | DDB1CRBN | |
| SCHEMBL30706226 | 0.82 | DDB1 (0.75) | DDB1CRBN | |
| SCHEMBL24671227 | 0.82 | DDB1 (0.61) | DDB1CRBNBRD4CDK7CDK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | DDB1 368/4885CRBN 249/4885BRD4 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.